{
    "clinical_study": {
        "@rank": "25012", 
        "arm_group": {
            "arm_group_label": "Patients undergoing renal denervation", 
            "arm_group_type": "Experimental", 
            "description": "patients diagnosed with resistant hypertension, eligible to undergo renal denervation"
        }, 
        "brief_summary": {
            "textblock": "Many studies have studied the effect and safety of renal denervation. However,  it remains\n      unknown what the exact mechanism behind renal denervation is. It can be hypothesized that a\n      difference in renal blood flow occurs after treatment. In the light of this ignorance,\n      current study will investigate whether renal denervation leads to a difference in renal\n      blood flow after treatment with renal denervation."
        }, 
        "brief_title": "The Effect of Renal Denervation on Renal Flow in Humans", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Individual is scheduled to undergo renal denervation as standard patient care for\n             resistant hypertension.\n\n          -  Individual is diagnosed with resistant hypertension. Secondary causes and a white\n             coat hypertension are actively excluded.\n\n          -  Individual is \u226518 years of age.\n\n          -  Individual agrees to have all study procedures performed, and is competent and\n             willing to provide written informed consent to participate in this clinical study.\n\n        Exclusion Criteria:\n\n          -  Individual is excluded from treatment with pRDN .\n\n          -  Individual has an estimated glomerular filtration rate (eGFR) of <30mL/min/1.73m2,\n             using the MDRD calculation.\n\n          -  Individual has experienced a myocardial infarction, unstable angina pectoris, or a\n             cerebrovascular accident within 6 months of the screening visit, or has widespread\n             atherosclerosis, with documented intravascular thrombosis or unstable plaques.\n\n          -  Individual has any serious medical condition, which in the opinion of the\n             investigator, may adversely affect the safety and/or effectiveness of the participant\n             or the study (i.e., patients with clinically significant peripheral vascular disease,\n             abdominal aortic aneurysm, bleeding disorders such as thrombocytopenia, haemophilia\n             or significant   anaemia).\n\n          -  Individual is pregnant, nursing or planning to be pregnant.\n\n          -  Individual has a known, unresolved history of drug use or alcohol dependency, lacks\n             the ability to comprehend or follow instructions, or would be unlikely or unable to\n             comply with study follow-up requirements."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01848314", 
            "org_study_id": "NL42766.041.12"
        }, 
        "intervention": {
            "arm_group_label": "Patients undergoing renal denervation", 
            "description": "Flowmeasurements will be performed before and after renal denervation", 
            "intervention_name": "Renal Denervation", 
            "intervention_type": "Procedure", 
            "other_name": "flowmeasurements"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 6, 2013", 
        "location": {
            "contact": {
                "email": "w.l.verloop@umcutrecht.nl", 
                "last_name": "Willemien Verloop, MD", 
                "phone": "0031887559447"
            }, 
            "contact_backup": {
                "email": "m.voskuil@umcutrecht.nl", 
                "last_name": "Michiel Voskuil"
            }, 
            "facility": {
                "address": {
                    "city": "Utrecht", 
                    "country": "Netherlands", 
                    "zip": "3584CX"
                }, 
                "name": "UMC Utrecht"
            }, 
            "investigator": {
                "last_name": "Willemien Verloop, MD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Effect of Renal Denervation on Renal Flow in Humans", 
        "other_outcome": {
            "measure": "safety of measurement", 
            "safety_issue": "Yes", 
            "time_frame": "within 24 hour after renal denervation"
        }, 
        "overall_contact": {
            "email": "w.l.verloop@umcutrecht.nl", 
            "last_name": "Willemien L. Verloop, MD", 
            "phone": "0031 88 7559447"
        }, 
        "overall_official": {
            "affiliation": "UMC Utrecht", 
            "last_name": "Michiel Voskuil, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: Medical Ethics Review Committee (METC)", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in microvascular resistance", 
            "safety_issue": "No", 
            "time_frame": "Within 30 minutes after renal denervation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01848314"
        }, 
        "responsible_party": {
            "investigator_affiliation": "UMC Utrecht", 
            "investigator_full_name": "W.I. Verloop", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "change in average flow velocity", 
            "safety_issue": "No", 
            "time_frame": "within 30 minutes after renal denervation"
        }, 
        "source": "UMC Utrecht", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "UMC Utrecht", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}